Creative Biolabs today announced a strategic enhancement to its multi-omics portfolio, focusing on precision NGS solutions optimized for 3D cell cultures, spheroids, and organoids.
SHIRLEY, NY, May 27, 2026 /24-7PressRelease/ — As the pharmaceutical industry faces ongoing challenges in translating laboratory discoveries into viable clinical therapies, 3D biological models—such as organoids and spheroids—are rapidly becoming the standard for physiological research. However, a significant bottleneck remains: effectively mapping the complex genomic profiles of these three-dimensional structures. To bridge this gap, biotechnology provider Creative Biolabs today announced a strategic enhancement to its next-generation sequencing (NGS) solutions, specifically tailored for complex 3D biology.
Standard 2D monolayer cell cultures frequently fail to replicate the true architectural distribution and genetic environments found in human tissues. To uncover massive structural variations and genetic blind spots across these complex models, researchers are increasingly relying on comprehensive mapping of the entire genome. Creative Biolabs’ unified pipeline pairs patient-derived 3D structures with this level of deep genomic confirmation, helping investigators improve translational relevance and support more clinically relevant modeling.
“Our goal is to provide a complete biological picture that helps researchers refine their lead validation process,” said a senior scientist from Creative Biolabs’ NGS department. For translational projects where cost-efficiency and functional disease-association studies are the priority, the platform adapts to offer high-depth targeted exome screening. This focused approach allows investigators to identify critical micro-variants in protein-coding regions without sacrificing speed or analytical accuracy.
Beyond structural DNA mapping, understanding the immediate biological responses of organoids is critical for oncology and targeted therapeutics. To support the “Analyze and Validate” stages of the discovery cycle, the company has integrated advanced transcriptomic capabilities. By utilizing dynamic RNA sequencing, biotech and pharma teams can effectively quantify real-time gene expression alterations and interpret alternative splicing events.
FAQ: 3D Biology Based NGS and Multi-Omics Optimization
How do researchers choose between WGS and WES for 3D models? WGS is ideal for uncovering structural variants and mutations within regulatory, non-coding regions across the entire genome. WES is recommended for focused disease-association studies, providing high-depth mutation screening specifically within protein-coding regions at a more accessible cost.
What are the primary deliverables of this multi-omics service? Clients receive high-quality raw sequencing data, a ranked list of identified variants/mutations, detailed bioinformatic liability reports, and visualized statistical figures mapping out transcriptomic or genomic alterations.
Key Takeaways
Integrated Workflow: Connects advanced 3D cell cultures with comprehensive genomic, exomic, and transcriptomic profiling.
Target Validation: Identifies base-by-base mutations, SNPs, and structural variations using clinical-associated 3D disease models.
Deep Coverage WES: Focuses on functional exon regions to maximize sequencing depth for low-frequency variants.
Translational Insights: High-throughput RNA-Seq supports real-time gene expression quantification and alternative splicing assessment.
By replacing highly technical barriers with streamlined, advanced bioinformatic analysis, this expanded capability provides high-quality raw data, ranked variant reports, and visualized biological alterations. To discuss customized study designs or connect with NGS specialists for your next 3D biology project, visit Creative Biolabs.
—
For the original version of this press release, please visit 24-7PressRelease.com here
Legal Disclaimer: This article was provided by an independent third-party content provider. Kyrion Media makes no warranties or representations in connection with it. All information is provided “as is” without warranty of any kind. This content may not have been reviewed by our editorial staff and is published automatically. The views expressed in this article are those of the author and do not necessarily reflect the views of Kyrion Media. All trademarks are the property of their respective owners. If you are affiliated with this article and would like it removed, please contact retract@kyrionmedia.com.
